

Alexei V Tulin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2211799/publications.pdf>

Version: 2024-02-01

34
papers

1,998
citations

331538

21
h-index

395590

33
g-index

34
all docs

34
docs citations

34
times ranked

1991
citing authors

#	ARTICLE	IF	CITATIONS
1	Chromatin Loosening by Poly(ADP)-Ribose Polymerase (PARP) at Drosophila Puff Loci. <i>Science</i> , 2003, 299, 560-562.	6.0	426
2	Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. <i>Genes and Development</i> , 2009, 23, 804-809.	2.7	190
3	The Drosophila heterochromatic gene encoding poly(ADP-ribose) polymerase (PARP) is required to modulate chromatin structure during development. <i>Genes and Development</i> , 2002, 16, 2108-2119.	2.7	187
4	The roles of PARP1 in gene control and cell differentiation. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 512-518.	1.5	126
5	Nucleosomal Core Histones Mediate Dynamic Regulation of Poly(ADP-ribose) Polymerase 1 Protein Binding to Chromatin and Induction of Its Enzymatic Activity. <i>Journal of Biological Chemistry</i> , 2007, 282, 32511-32519.	1.6	96
6	Poly(ADP-Ribose) Polymerase 1 (PARP-1) Regulates Ribosomal Biogenesis in Drosophila Nucleoli. <i>PLoS Genetics</i> , 2012, 8, e1002442.	1.5	85
7	Poly(ADP-ribosyl)ation of heterogeneous nuclear ribonucleoproteins modulates splicing. <i>Nucleic Acids Research</i> , 2009, 37, 3501-3513.	6.5	84
8	Poly (ADP-Ribose) Polymerase 1 Is Required for Protein Localization to Cajal Body. <i>PLoS Genetics</i> , 2009, 5, e1000387.	1.5	71
9	Poly-ADP-ribose polymerase: Machinery for nuclear processes. <i>Molecular Aspects of Medicine</i> , 2013, 34, 1124-1137.	2.7	71
10	Hit and run versus long-term activation of PARP-1 by its different domains fine-tunes nuclear processes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9941-9946.	3.3	63
11	<i>Drosophila</i> histone H2A variant (H2Av) controls poly(ADP-ribose) polymerase 1 (PARP1) activation in chromatin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6205-6210.	3.3	61
12	Post-Transcriptional Regulation by Poly(ADP-ribosyl)ation of the RNA-Binding Proteins. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16168-16183.	1.8	56
13	Bookmarking promoters in mitotic chromatin: poly(ADP-ribose)polymerase-1 as an epigenetic mark. <i>Nucleic Acids Research</i> , 2014, 42, 7028-7038.	6.5	56
14	Uncoupling of the transactivation and transrepression functions of PARP1 protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6406-6411.	3.3	54
15	Regulation of Chromatin Structure and Gene Activity by Poly(ADP-Ribose) Polymerases. <i>Current Topics in Developmental Biology</i> , 2003, 56, 55-83.	1.0	53
16	Drosophila Poly(ADP-Ribose) Glycohydrolase Mediates Chromatin Structure and SIR2-Dependent Silencing. <i>Genetics</i> , 2006, 172, 363-371.	1.2	53
17	Poly(ADP-ribose) controls DE-cadherin-dependent stem cell maintenance and oocyte localization. <i>Nature Communications</i> , 2012, 3, 760.	5.8	48
18	Kinase-Mediated Changes in Nucleosome Conformation Trigger Chromatin Decondensation via Poly(ADP-Ribosyl)ation. <i>Molecular Cell</i> , 2014, 53, 831-842.	4.5	39

#	ARTICLE	IF	CITATIONS
19	Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo. EBioMedicine, 2016, 13, 90-98.	2.7	38
20	Minor groove binding ligands disrupt PARP-1 activation pathways. Oncotarget, 2014, 5, 428-437.	0.8	22
21	Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical Pharmacology, 2019, 167, 149-162.	2.0	21
22	Re-evaluating PARP1 inhibitor in cancer. Nature Biotechnology, 2011, 29, 1078-1079.	9.4	18
23	Small-Molecule Collection and High-Throughput Colorimetric Assay to Identify PARP1 Inhibitors. Methods in Molecular Biology, 2011, 780, 491-516.	0.4	13
24	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leukemia and Lymphoma, 2019, 60, 1098-1101.	0.6	12
25	Poly(ADP-Ribosyl)ation of hnRNP A1 Protein Controls Translational Repression in <i>Drosophila</i> . Molecular and Cellular Biology, 2016, 36, 2476-2486.	1.1	10
26	Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy. Cancers, 2021, 13, 4973.	1.7	10
27	Poly(ADP-ribose) polymerase 1 in genome-wide expression control in <i>Drosophila</i> . Scientific Reports, 2020, 10, 21151.	1.6	9
28	Age-Related Changes of Gene Expression Profiles in <i>Drosophila</i> . Genes, 2021, 12, 1982.	1.0	8
29	Poly(ADP-ribose)ating pathway regulates development from stem cell niche to longevity control. Life Science Alliance, 2022, 5, e202101071.	1.3	5
30	Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. Medicinal Chemistry Research, 2020, 29, 962-978.	1.1	4
31	PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment. BMC Cancer, 2022, 22, 557.	1.1	4
32	High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection. Methods in Molecular Biology, 2017, 1608, 299-312.	0.4	3
33	Structurally unique PARP1 inhibitors for the treatment of prostate cancer. Pharmacology Research and Perspectives, 2020, 8, e00586.	1.1	2
34	PARP-1 Interaction with and Activation by Histones and Nucleosomes. Methods in Molecular Biology, 2017, 1608, 255-267.	0.4	0